Stocks
Longeveron Sets August 2026 ELPIS II Readout, Adopts Asset-Light Model
Longeveron (LGVN) targets an August 2026 readout for its ELPIS II study, simultaneously shifting to an asset-light partnering model under new leadership....

Longeveron (LGVN) targets an August 2026 readout for its ELPIS II study, simultaneously shifting to an asset-light partnering model under new leadership....

Vaxart (VXRT) anticipates a primary efficacy readout for its oral vaccine platform in early 2027, with a Q2 sentinel data release expected...

AstraZeneca (AZN) announced a successful late-stage trial for its Imfinzi combination regimen in a subset of liver cancer patients, bolstering the company's...